Anti-VEGFR therapy is one of the healing inhibitors of antiresorptive-related osteonecrosis of the jaw.

摘要: Antiresorptive-related osteonecrosis of the jaw (ARONJ) is a rare but serious adverse event associated with bone-modifying agents (BMAs) and affects patients in terminal stages cancer. Molecular targeting drugs (MTDs), anti-vascular endothelial growth factor receptor (VEGFR), anti-epidermal (EGFR) are essential various cancer treatments, although MTDs risk factors for ARONJ. However, mechanism through which affect treatment prognosis ARONJ remains unclear. Therefore, we investigated potential inhibitory healing conservative therapy focus on MTDs. Sixty who were administered BMAs malignancies underwent assessed. The rate each was retrospectively evaluated. Among 60 patients, 27 male 33 female. median age 67 years, follow-up period 292 (range 91–1758) days. lower those treated both zoledronic acid (Za) denosumab (Dmab) than Za or Dmab alone (0% vs. 28.8%, p = 0.03). Regarding administration MTDs, anti-VEGFR 7.1% (p = 0.04), anti-EGFR 12.5% (p = 0.18), without 36.8%. In ARONJ, several contributing to inhibition healing.